Greetings, and welcome to Sanuwave's Q2 Business Update Call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. It is now my pleasure to introduce your host, Kevin Richardson, Chief Executive Officer. Thank you. You may begin. Thank you, Doug. Today, we will review Q2 results, discuss our outlook, and provide revenue guidance for the rest of 2022. Joining me on the call today are Jack Heil, our Chief Revenue Officer, and Toni Rinow, our newly announced CFO. We have provided an eight-page slide presentation to help our investors understand our results and our framework for growth. The slides are available on the Sanuwave website under the Investor News section. On the slide presentation, please spend time reviewing the obligatory forward-looking statement, as we will be reviewing guidance for 2022. We're using the Q2 results and filing to put the late filing chapter behind us and begin to look forward at the growth opportunity we have in front of us. We're now fully positioned to achieve the growth opportunity in the wound care space that Sanuwave can achieve. We have two products that treat chronic advanced wounds, UltraMIST and dermaPACE. Both products use energy, ultrasound waves and focused shockwaves, to stimulate the body to rejuvenate and repair itself. Clinically, the products have superior results. The products are easy to use and adjust quickly into the clinic's and wound care facilities' workflow. Reimbursement continues to rise and is robust, allowing the clinics and physicians to get a high return on investment with using these products. Based on the positive outcomes that our products generate clinically, we do see that those reimbursement rates can continue to climb in the near future. With the reimbursement as strong as it is, it is also important to know that the clinically, we close the wounds for less expense than many other advanced therapies. Our products heal effectively, pay the clinics and physicians nicely, and save the system money. It's a great recipe for success. Jack will discuss the current outlook and what we have in hand today. Suffice it to say, we have a long way to grow as we add back salespeople, add new verticals, and become part of a standard protocol in some of the major wound care practices. We think the sky's the limit. Let me turn the presentation over now to Toni Rinow, our newly announced CFO. Jack will then cover the pipeline and sales metrics, and I will conclude with some initial revenue guidance for 2022. Toni. Thank you, Kevin. First of all, I would like to thank the Sanuwave team for the warm welcome. This is a great team, and Sanuwave has a bright future with continuously increasing revenue and on a path to break even and future profitability. Using my past experience as CFO in international, publicly traded, and private equity health organizations, I'm looking forward to contribute to the financial leadership on Sanuwave's growth path. Revenues for Q2, ending June 30th, amounted to $3.9 million, an increase of $1 million over the same period last year. This is an increase of 33% driven by UltraMIST sales. The company moved manufacturing from Georgia to Minnesota, which impacted timing of international shipments, resulting in $100,000 reduction in international revenue year-over-year. Gross margin increased to 72% from 64%. The improvements were driven due to product mix and more effective customer service and logistics and improvements in supply chain management. OpEx was down $1 million, driven by lower sales and marketing expenses and R&D costs. Looking forward, we expect Q3 to be similar to Q2 and Q4 to begin to see benefits of additional cost-saving initiatives, likely to be offset by increase in sales and marketing due to some incremental hiring. Thank you all for your continued support of Sanuwave. Over to Kevin and Jack. Great. Jack, if you could walk us through slide deck and just to reference people. Sure. Jack will be covering slides five, six, and seven on the slide deck that is available on our investor website. Yeah. Thank you, Kevin. Thank you, Toni. We are excited with the growth of our portfolio and continue to focus on our accounts and expanding Sanuwave's footprint with the Energy First platform. We have a small but strong committed sales team and look forward to new additions in key markets over the next several months. When we look at slide five, illustrating our pipeline and our growth that we've seen quarter-over-quarter and year-over-year. Our trials are our pipeline and our lifeblood. Our typical trials last anywhere from 60-90 days and allow our customers to assess the benefits of our energy products, both clinically and financially. Last year, 2021, at this time, we had 44 trials valued at $1.5 million. Last quarter, we had 66 trials valued at $1.9 million. I'm pleased to announce that ending June, we had 94 trials valued at $3.1 million, up 100% year-over-year. For the first time, we have a backlog of 96 trials, which we are actively trying to fill and engage with those new customers, and we value those systems at $3 million. Great growth and market penetration year-over-year, and we were able to accomplish this growth with 33% less salespeople. Our team is truly focused on healing patients with the Energy First platform. We're starting as the Energy First platform is accepted by large national chains. We are seeing growth in new markets and verticals such as skilled nursing facilities, cosmetics, and sports medicine, while in some cases even becoming the standard of care. We have a great deal of potential and interest in both of our products and look forward to some big wins in the near future. When you look at slide six, we continue to expand our footprint in new accounts, adding 161 accounts by the end of this year, when we expect to be at 688 accounts, an overall increase of 30%. We do so by targeting new accounts and focused on applicator sales and our increasing demand in the areas that I mentioned previously. We have the ability to do so based on our current pipeline. On slide seven, we continuously assess our business and look at our accounts in driving more recurring revenue. We are focused on increasing new accounts and increasing the number of monthly treatments. Currently, we have 527 active accounts. Each of those accounts administer 25 treatments a month, and our top 100 accounts administer 102 treatments per month, while the remaining accounts treat 7.4 patients per month. As a sales team, we are working with lower volume accounts to increase the monthly usage. We have identified dormant accounts and are reengaging with them. The goal is to increase the base book of business and increase the recurring revenue in these accounts. The team is focused on selling systems, increasing new accounts, and reengaging with dormant accounts that were lost. This started in July, and we've already seen success in sales generated. The final piece is a system upgrade across all of our accounts to collect data and also offer another touch point for all of the accounts. We are excited about the remainder of 2022 and optimistic on our trajectory. Kevin, I'll turn it back over to you. Great. Thank you, Jack. Thank you, Toni. We're gonna now go through slide eight, which is our guidance for 2022. It's our first attempt at guidance in a long time, and we wanted to explain how we arrive at that guidance. We'll have $18 million of revenue, that's up from $13 million the prior year, and operating profitability in Q4. The guidance is based on what we have in hand currently. They're based on the numbers Jack reviewed, which are the evals and trials that are taking place currently and the backlog of evals that will begin taking place over the coming months, and using our historic close rates on those, to determine what the revenue will be for the remainder of the year. We also have the other initiatives that we've talked about of re-engaging dormant accounts and driving more usage. Those are all baked into the $18 million. We do have a large number of system sales that could be with bigger, larger customers. We don't include those in guidance because they're going to be very lumpy, they're gonna be very big. Until we're 100% certain we can deliver the product and have the implementation teams to support those customers, we're not gonna include those in guidance. When we do have those announced and feel comfortable with that, we will add that to guidance in the future. We also do not include sports med or cosmetics in guidance at this point in time. Breakeven's also important for us, so we don't have to go back to the market to fund ongoing operating losses. A big initiative this year is getting to that profitability in Q4. Given our recent successful funding that we had with existing, supportive investors, we're now positioned to turn on more growth from our supply chain, add additional sales team members, and accelerate the top line as we head into 2023. I'm gonna stop there. We're gonna open it up to questions to Tony, myself, or Jack. Just one final thing, thank you for supporting us as we've gone through this to kinda Sanuwave 2.0 as we now move forward. We'll open up to questions. Thank you. Ladies and gentlemen, at this time, we'll be conducting a question and answer session. If you'd like to ask a question, you may press star one on your telephone keypad. Confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. Our first question comes from the line of Sachin Shah. Please proceed with your question. Hey, Kevin. How are you? Good. How are you, Sachin? Good. Great presentation, like you said, with Sanuwave 2.0 sort of starting to, I guess, one of the questions as a long-term investor now is, you know, how are we gonna see this company sort of get back onto the OTCQB, and then eventually, what is the plan to kinda get back or not get back, but to get to Nasdaq so that the institutional community can, you know, have an opportunity to get involved. Great. Thank you, Sachin. Let me first address OTC, then I'll address Nasdaq. With the OTC, we were moved to the what are called the OTC gray markets in September of last year when we did not get our 10-K for the prior year filed on time. We have since moved to the OTC Pink Sheets because we have gotten our filings done on time. The application process to get on the OTCQB has been started. It could be anywhere from two weeks to 10 weeks. The group that we're working with thinks it'll be on the faster side. As that happens and gets announced, we'll let investors know. What it allows for is a different type of market makers and solicited bids and so forth. It also makes it easier for the transactions to occur with some of the brokerage firms that are out there for individual investors. The next step would be to move to Nasdaq, and there's a process that has been put in place underway. We'll be working with our investment advisor, Kestrel, on this process. We've got an independent board. We've separated the CEO and chairman role. That's a recent thing. We added three new board members in April. We added a fourth as part of the transaction recently that happened. That's part of the process to get ready for Nasdaq. There are certain requirements that we will have to wait on. Specifically, there's a certain number of regulatory filings that you have shown that you aren't late with. Also there's certain requirements on your balance sheet that you need. It is a process. It probably will not occur in 2022. It'll occur in early 2023. It's one of the requirements that came with the recent raise is to get up to Nasdaq and become an investable company. That's for institutions. That's one of the processes that's underway. Now we have a team in place that I think can execute on that as we build out the accounting and finance function and are timely on our filings consistently. Great. Thanks. Then I don't know if you can sort of forecast a little bit even more ahead into 2023 as all your engines are sort of revving now in the same direction, and your focus now will sort of turn from accounting issues and integration to growth, like you said. In your estimate, what would be sort of success for you in terms of Sanuwave and revenue growth for 2023, if you can even comment on that? The wound care market's going through a lot of change, but our products should be in every wound care center. It should be anywhere that a chronic wound exists. I, you know, I guess that's an awful large footprint. Right. Sachin. I mean, that's billions of dollars of opportunity. You know, there's that old proverb, how do you eat an elephant? It's you know, one bite at a time. We have to execute and keep adding one eval, one device, make sure they're using it. It really comes down to just execution with the team, where they're making sure we're penetrating markets and getting patients, you know, wounds healed, lives saved, and there's a good economic return for the center, and there's also cost savings for the payer. We're a unique product set where we can actually have the physician actually make more money than he would with other products, yet at the same time save money relative for the payer. It's a very unique situation that clinically heal the wound faster. We have. We're really in a unique situation where there shouldn't be anything that slows us down other than having the resources to build it out. Now with the recent raise that was completed, we can get our supply chain up and running and cranking. We can hire the right sales team, do some more clinical work if that's what's needed to get into the private payer market a little more aggressively. Those are the types of initiatives, Sachin, that we're working on. Okay. Thanks, Kevin. Thank you, Sachin. As a reminder, it's star one to ask a question. There are no more questions in the queue. I'd like to hand the call back to Mr. Richardson for closing remarks. Well, thank you everyone for joining us, and thank you for supporting us as we're now positioning kinda Sanuwave 2.0 for rapid growth the remainder of this year, accelerating into next year. If you have any questions, as always, feel free to reach out. If you have any other items that you think you would be beneficial to ask, please let us know so we can incorporate them into the business. Thank you very much, and have a great day. Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.